Abstract：
:Thirty-two adult patients with acute leukemia were treated with continuous infusion carboplatin and etoposide at eight different dose levels. Dose limiting toxicity was encountered at doses of carboplatin of 310 mg/m2 per day for 5 days (total 1550 mg/m2 per course) and etoposide 150 mg/m2 per day for 5 days (total dose 750 mg/m2 per course) and consisted primarily of gastrointestinal toxicity. Of the five courses given at the highest dose level, three were complicated by grade 4 gastrointestinal toxicity. The recommended dose for further phase II evaluations in acute leukemia is carboplatin 250 mg/m2 per day for 5 days by continuous infusion and etoposide 150 mg/m2 per day for 5 days given by continuous infusion. The response to treatment was notable for a single complete remission achieved in a patient with acute undifferentiated leukemia. None of the patients with chronic myeloid leukemia in blast crisis (n = 12) or with acute lymphocytic leukemia (n = 4) or acute myeloid leukemia (AML) (n = 15) achieved complete remission (CR), although all patients with AML entered on this trial had prior complete remissions that were less than 1 year in duration, and many were refractory, either to primary therapy or to the most recent attempt to obtain CR.
journal_name
Leukemiajournal_title
Leukemiaauthors
Lee EJ,Reck K,Carter C,Hodges S,Schiffer CAsubject
Has Abstractpub_date
1993-10-01 00:00:00pages
1500-3issue
10eissn
0887-6924issn
1476-5551journal_volume
7pub_type
临床试验,杂志文章相关文献
LEUKEMIA文献大全abstract：:In this study, we investigated the responses of the T cell leukaemia cell line, CCRF-CEM, and a vincristine-resistant subline, CEM/VCR R, to the induction of cell death by serum withdrawal. This treatment was used to overcome any contribution of P-glycoprotein-mediated drug resistance to the responses of the CEM/VCR R...
journal_title：Leukemia
pub_type： 杂志文章
doi：
更新日期：1996-03-01 00:00:00
abstract：:Proliferation in vitro of the murine hemopoietic cell line FDC-P1 is dependent on stimulation by granulocyte-macrophage colony stimulating factor or multipotential colony stimulating factor. Although immortalized, the cells are not tumorigenic on subcutaneous inoculation. Intravenous injection of FDC-P1 cells into syn...
journal_title：Leukemia
pub_type： 杂志文章
doi：
更新日期：1988-06-01 00:00:00
abstract：:To assess the efficacy and toxicity of HAA regimen (homoharritonine 4 mg/m2/day, days 1-3; cytarabine 150 mg/m2/day, days 1-7; aclarubicin 12 mg/m2/day, days 1-7) as an induction therapy in the treatment of de novo acute myeloid leukemia (AML), 48 patients with newly diagnosed AML, aged 35 (14-57) years, were entered ...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/sj.leu.2404287
更新日期：2006-08-01 00:00:00
abstract：:Only two classes of chemotherapeutic agents have shown activity in acute myeloid leukemia (AML): ara-C and topoisomerase II reactive agents. Frontline combinations of these agents produce complete response (CR) rates of 70% and long-term event free survival rates of 25%. New agents with different mechanisms of action ...
journal_title：Leukemia
pub_type： 杂志文章,评审
doi：
更新日期：1996-04-01 00:00:00
abstract：:Depending on disease stage follicular lymphoma (FL) lack the t(14;18) in ~15-~50% of cases. Nevertheless, most of these cases express BCL2. To elucidate mechanisms triggering BCL2 expression and promoting pathogenesis in t(14;18)-negative FL, exonic single-nucleotide variant (SNV) profiles of 28 t(14;18)-positive and ...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/leu.2017.270
更新日期：2018-03-01 00:00:00
abstract：:Despite recent advances in our understanding of the molecular and biological abnormalities in chronic myelogenous leukemia (CML) this new knowledge has not yet led to significant improvements in treatment. We have reviewed what is known and still unknown about the molecular and biological abnormalities in CML that may...
journal_title：Leukemia
pub_type： 杂志文章,评审
doi：
更新日期：1993-11-01 00:00:00
abstract：:The efficacy of antifungal prophylaxis with itraconazole capsules and its serum concentrations were evaluated in patients intensively treated for acute leukaemia. A consecutive group of patients without systemic antifungal prophylaxis (January 1993 to August 1994, period 1) was compared with another consecutive group ...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/sj.leu.2401137
更新日期：1998-09-01 00:00:00
abstract：:Imatinib is a highly effective therapy for chronic phase-chronic myeloid leukaemia (CP-CML) patients; however, responses to frontline imatinib are variable. The human organic cation transporter 1 (OCT1; SLC22A1) has been reported to be the main influx transporter involved in imatinib uptake into CML cells. Furthermore...
journal_title：Leukemia
pub_type： 杂志文章,评审
doi：10.1038/leu.2015.170
更新日期：2015-10-01 00:00:00
abstract：:Immunophenotypes and Ig gene rearrangements were investigated in 12 patients with a variant form of hairy cell leukemia (HCL) termed HCL-Japanese variant (HCL-J), and in an HCL-J-derived cell line. The leukemic cells of HCL-J characteristically showed the phenotype of CD20+, CD5-, CD10-, CD11c+, CD22+, CD24- and CD25-...
journal_title：Leukemia
pub_type： 杂志文章
doi：
更新日期：1996-08-01 00:00:00
abstract：:We have analyzed the expression of Tdt and CD7 in 335 cases of unequivocal acute myeloid leukemia (AML). Tdt was expressed in 80 (25%) of 321 evaluable cases. Twenty-six of 77 (34%) Tdt+ patients assessable for response, entered complete remission (CR) vs 121 of 209 (58%) Tdt- cases (P < 0.001). CD7 was expressed in 1...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/sj.leu.2401067
更新日期：1998-07-01 00:00:00
abstract：:We have previously shown that all-trans retinoic acid (ATRA) increases the number of CFU-GM colonies grown from unseparated human bone marrow cells with crude sources of colony stimulating factors. In this study, we further characterized the effect of ATRA on the growth of CFU-GM stimulated by individual cytokines fro...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/sj.leu.2401772
更新日期：2000-05-01 00:00:00
abstract：:The requirement that leukemic Gata1 mutations be present in cells harboring trisomy 21 led to the discovery that overexpression of ERG drives aberrant megakaryopoiesis. Given that constitutive PI3K/AKT signaling is a frequent component of hematologic malignancies and the relationship between AKT and Notch in this line...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/leu.2013.33
更新日期：2013-06-01 00:00:00
abstract：:Highly polymorphic tandemly repetitive DNA sequences provide powerful genetic markers for the identification of individuals by restriction fragment length polymorphisms (RFLP) even in close relatives. Over a three-year period, 61 consecutive patients from a single institution undergoing allogeneic bone marrow transpla...
journal_title：Leukemia
pub_type： 杂志文章
doi：
更新日期：1993-05-01 00:00:00
abstract：:The cyclin-dependent kinase inhibitors known as p15, p16, p18 and p19 have been suggested as candidates for tumor suppressor genes. The main genetic alterations are deletions (bi- or monoallelic) or 5' CpG island methylation of p15 and p16; very few cases or cell lines had p18 or p19 deletions or hypermethylation. Hyp...
journal_title：Leukemia
pub_type： 杂志文章,评审
doi：10.1038/sj.leu.2401043
更新日期：1998-06-01 00:00:00
abstract：:The effects of retinoic acid (RA) on the cell growth and expression of interleukin-2 (IL-2) receptors (IL-2R alpha/p55, Tac, CD25) by the human T lymphotropic virus type I (HTLV-I)-positive T cell lines, HUT102 and ATL-2 were investigated. Incubation of these cells for 48 h with either 13-cis retinoid acid (13-cis RA)...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/sj.leu.2400593
更新日期：1997-03-01 00:00:00
abstract：:Peripheral arterial occlusive disease (PAOD) occurs in patients with chronic phase chronic myeloid leukemia (CML-CP) treated with tyrosine kinase inhibitors (TKIs). The risk of developing PAOD on TKI therapy is unknown and causality has not been established. Patients with CML-CP from three randomized phase III studies...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/leu.2013.69
更新日期：2013-06-01 00:00:00
abstract：:It has been suggested that abnormalities of chromosome 3 at bands q21 and q26 are associated with the presence of increased numbers of abnormal megakaryocytes in patients with hematologic malignancies. The pretreatment bone marrows of 287 patients with leukemia (acute myeloid leukemia (AML), 225 patients; acute lympho...
journal_title：Leukemia
pub_type： 杂志文章
doi：
更新日期：1990-05-01 00:00:00
abstract：:The observation that wild type p53 may induce cells to undergo either apoptosis or differentiation raises the question of whether these two events share similar p53-dependent pathways. To evaluate the interrelationship between these two p53-dependent processes, our study focused on the human HL-60, a pro-myelocytic p5...
journal_title：Leukemia
pub_type： 杂志文章
doi：
更新日期：1997-04-01 00:00:00
abstract：:We investigated the expression of P-glycoprotein (P-gp) in 52 adults with de novo acute myelogenous leukemia (AML) at the initial diagnosis. We tested 52 patients by flow cytometry using the MRK16 monoclonal antibody (MoAb). To investigate the phenotype for multidrug resistance, 41 of the patients were analyzed using ...
journal_title：Leukemia
pub_type： 杂志文章
doi：
更新日期：1994-09-01 00:00:00
abstract：:To evaluate current detection methods for FIP1L1-PDGFRA in hypereosinophilic syndrome (HES), we developed a means to rapidly amplify genomic break points. We screened 202 cases and detected genomic junctions in all samples previously identified as RT-PCR positive (n=43). Genomic fusions were amplified by single step P...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/leu.2008.309
更新日期：2009-02-01 00:00:00
abstract：:Currently available data regarding the substrate specificity of the multi-drug resistance (MDR) mechanisms P-glycoprotein (Pgp) and MDR-associated protein (MRP1) for idarubicin are inconclusive. A multiparameter flow cytometry method was developed which allows simultaneous quantitative measurement of total cellular fl...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/sj.leu.2401496
更新日期：1999-09-01 00:00:00
abstract：:We applied a new strategy for the detection of N-ras gene mutations based on LightCycler technology. We designed two sets of amplimers and internal hybridization probes representing N-ras codons 12/13 and codon 61, respectively. Genomic DNAs from 134 childhood acute lymphoblastic leukemia (ALL) patients (83 common ALL...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/sj.leu.2401645
更新日期：2000-02-01 00:00:00
abstract：:Less-intense remission induction regimens for adults with newly diagnosed acute myeloid leukemia (AML) aim to reduce treatment-related mortality (TRM), here defined as death within 4 weeks after starting induction therapy. This assumes that TRM rates are similar to the 15-20% observed 20 years ago. Herein we test this...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/leu.2013.176
更新日期：2014-02-01 00:00:00
abstract：:Preliminary evidence suggests that the multikinase inhibitor sorafenib has clinical activity in FLT3-ITD-positive (FLT3-ITD) acute myeloid leukemia (AML). However, the quality and sustainability of achievable remissions and clinical variables that influence the outcome of sorafenib monotherapy are largely undefined. T...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/leu.2012.105
更新日期：2012-11-01 00:00:00
abstract：:The major cause of early death in acute promyelocytic leukemia (APL), the high risk of a bleeding diathesis is now successfully counteracted within a few days by differentiation therapy using ATRA. Moreover, no resistance to this drug has been recorded during induction when the usual presence of PML/RAR alpha was conf...
journal_title：Leukemia
pub_type： 杂志文章
doi：
更新日期：1994-01-01 00:00:00
abstract：:Allogeneic and autologous stem cell transplantation (SCT) are increasingly considered for treatment of patients with chronic lymphocytic leukemia (CLL). In order to assess the potential therapeutic value of SCT for CLL, the present article aims at answering the following crucial questions: (1) Is SCT a curative treatm...
journal_title：Leukemia
pub_type： 杂志文章,评审
doi：10.1038/sj.leu.2402530
更新日期：2002-06-01 00:00:00
abstract：:Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by the presence of circulating plasma cells. It is classified as either primary PCL occurring at diagnosis or as secondary PCL in patients with relapsed/refractory myeloma. Primary PCL is a distinct clinic-pathological entity with dif...
journal_title：Leukemia
pub_type： 杂志文章,评审
doi：10.1038/leu.2012.336
更新日期：2013-04-01 00:00:00
abstract：:Both conventional chimerism analysis (CCA) and lineage-specific chimerism analysis (LCA) have potential pitfalls as diagnostic means for the detection of minimal residual disease after allogeneic hematopoietic cell transplantation (aHCT). Therefore, the present study examines the results of both methods in order to de...
journal_title：Leukemia
pub_type： 杂志文章
doi：10.1038/sj.leu.2403719
更新日期：2005-05-01 00:00:00
abstract：:We have examined the respiratory status of murine and human marrow progenitor cells proliferating in response to growth factors. Proliferation of fresh marrow cells, which are almost entirely entering terminal differentiation, depends on oxidative phosphorylation as determined by oxygen uptake, lactic acid production,...
journal_title：Leukemia
pub_type： 杂志文章
doi：
更新日期：1987-07-01 00:00:00
abstract：:Osteolytic bone disease in multiple myeloma (MM) is caused by enhanced osteoclast (OCL) activation and inhibition of osteoblast function. Lenalidomide and bortezomib have shown promising response rates in relapsed and newly diagnosed MM, and bortezomib has recently been reported to inhibit OCLs. We here investigated t...
journal_title：Leukemia
pub_type： 杂志文章,随机对照试验
doi：10.1038/leu.2008.174
更新日期：2008-10-01 00:00:00
